Leerink Partners lowers Moderna stock price target to $18 on cost cuts

Published 04/08/2025, 18:00
© Reuters

Investing.com - Leerink Partners lowered its price target on Moderna (NASDAQ:MRNA) stock to $18.00 from $20.00 on Monday, while maintaining an Underperform rating following the company’s recent earnings call. The stock, currently trading at $27.28 with a market cap of $10.63 billion, has declined 18.59% in the past week alone.

The research firm noted Moderna’s aggressive cost-cutting measures, particularly highlighting a 43% year-over-year reduction in R&D expenses, which it described as "promising signs" that the company is working to optimize its cost structure amid steep revenue declines.

Despite these cost reductions, Leerink Partners indicated that the savings primarily offset revenue lost to delayed overseas COVID vaccine deliveries, resulting in unchanged year-end 2025 cash guidance of $6 billion.

The firm identified several key focus areas for Moderna, including upcoming ACIP COVID recommendations and the company’s ability to reverse revenue decline with its mNexspike launch, while questioning how receptive payers will be to Moderna’s premium pricing strategy.

Beyond COVID vaccines, Leerink Partners expressed concerns about Moderna’s CMV vaccine candidate, suggesting that recent trial developments, including a first interim miss and changes to the analysis plan, indicate "odds of a trial success are dwindling."

In other recent news, Moderna reported its second-quarter 2025 earnings, surpassing forecasts on both earnings per share and revenue. The company achieved an actual EPS of -2.13, beating the expected -2.98, and reported revenue of 142 million dollars, exceeding the forecasted 114.4 million dollars. Despite these better-than-expected results, Moderna’s stock experienced a decline in premarket trading due to investor concerns about future challenges. Additionally, Moderna announced further cost reductions for 2025, but also lowered its revenue guidance, which UBS noted could disappoint some investors. UBS maintained its Buy rating and $70.00 price target on Moderna’s stock. In contrast, BofA Securities lowered its price target for Moderna to $24.00 from $25.00, citing a decreased terminal growth assumption and long-term growth uncertainty. BofA continues to rate the stock as Underperform. These developments highlight the mixed sentiment surrounding Moderna’s financial outlook.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.